Explore more
BioMarin Pharmaceutical Inc. has advancements in phenylketonuria treatment. Click to learn how Palynziq's success could ...
Clinical Trials Arena on MSN1d
BioMarin’s trial for phenylketonuria therapy meets primary efficacy endpointBioMarin Pharmaceutical has reported that the multi-centre Phase III PEGASUS trial of Palynziq (pegvaliase-pqpz) has met its ...
We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a ...
In a report released today, Joon Lee from Truist Financial maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report). The ...
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released topline data from the Phase 3 PEGASUS trial evaluating Palynziq ...
StockNews.com lowered shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) from a strong-buy rating to a buy rating ...
Pharmaceutical announced that the Phase 3 PEGASUS trial evaluating Palynziq met its primary efficacy endpoint, demonstrating a ...
San Rafael, California Thursday, April 3, 2025, 18:00 Hrs [IST] ...
Zacks.com on MSN1d
BMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric StudyBased on the late-stage data, BioMarin plans to submit a regulatory filing for expanding the label of its PKU drug Palynziq in adolescents before this year's end.
SAN RAFAEL, CA, USA I April 2, 2025 I BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Phase 3 PEGASUS trial evaluating PALYNZIQ ® (pegvaliase-pqpz) met its primary efficacy ...
US biotech BioMarin Pharmaceutical (Nasdaq: BMRN) yesterday revealed that the Phase III PEGASUS trial evaluating Palynziq (pegvaliase-pqpz) met its primary efficacy endpoint, demonstrating a ...
PR Newswire SAN RAFAEL, Calif., April 2, 2025 Company plans to submit for regulatory approval later this year SAN RAFAEL, Calif., April 2, 2025 /PRNewswire/ -- BioMarin Pharmaceut ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback